These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 30258894)

  • 1. Targeting glutamine metabolism in
    Feng X; Hao Y; Wang Z
    Genes Dis; 2016 Dec; 3(4):241-243. PubMed ID: 30258894
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oncogenic PIK3CA mutations reprogram glutamine metabolism in colorectal cancer.
    Hao Y; Samuels Y; Li Q; Krokowski D; Guan BJ; Wang C; Jin Z; Dong B; Cao B; Feng X; Xiang M; Xu C; Fink S; Meropol NJ; Xu Y; Conlon RA; Markowitz S; Kinzler KW; Velculescu VE; Brunengraber H; Willis JE; LaFramboise T; Hatzoglou M; Zhang GF; Vogelstein B; Wang Z
    Nat Commun; 2016 Jun; 7():11971. PubMed ID: 27321283
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Colorectal cancers utilize glutamine as an anaplerotic substrate of the TCA cycle in vivo.
    Zhao Y; Zhao X; Chen V; Feng Y; Wang L; Croniger C; Conlon RA; Markowitz S; Fearon E; Puchowicz M; Brunengraber H; Hao Y; Wang Z
    Sci Rep; 2019 Dec; 9(1):19180. PubMed ID: 31844152
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thyroid hormone regulates glutamine metabolism and anaplerotic fluxes by inducing mitochondrial glutamate aminotransferase GPT2.
    Cicatiello AG; Sagliocchi S; Nappi A; Di Cicco E; Miro C; Murolo M; Stornaiuolo M; Dentice M
    Cell Rep; 2022 Feb; 38(8):110409. PubMed ID: 35196498
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Deactivation of Glutaminolysis Sensitizes
    Boku S; Watanabe M; Sukeno M; Yaoi T; Hirota K; Iizuka-Ohashi M; Itoh K; Sakai T
    Cancers (Basel); 2020 Apr; 12(5):. PubMed ID: 32365457
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glutamic Pyruvate Transaminase GPT2 Promotes Tumorigenesis of Breast Cancer Cells by Activating Sonic Hedgehog Signaling.
    Cao Y; Lin SH; Wang Y; Chin YE; Kang L; Mi J
    Theranostics; 2017; 7(12):3021-3033. PubMed ID: 28839461
    [TBL] [Abstract][Full Text] [Related]  

  • 7. XIAP-targeting drugs re-sensitize PIK3CA-mutated colorectal cancer cells for death receptor-induced apoptosis.
    Ehrenschwender M; Bittner S; Seibold K; Wajant H
    Cell Death Dis; 2014 Dec; 5(12):e1570. PubMed ID: 25501831
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Loss of function mutation in glutamic pyruvate transaminase 2 (GPT2) causes developmental encephalopathy.
    Celis K; Shuldiner S; Haverfield EV; Cappell J; Yang R; Gong DW; Chung WK
    J Inherit Metab Dis; 2015 Sep; 38(5):941-8. PubMed ID: 25758935
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutations in mitochondrial enzyme GPT2 cause metabolic dysfunction and neurological disease with developmental and progressive features.
    Ouyang Q; Nakayama T; Baytas O; Davidson SM; Yang C; Schmidt M; Lizarraga SB; Mishra S; Ei-Quessny M; Niaz S; Gul Butt M; Imran Murtaza S; Javed A; Chaudhry HR; Vaughan DJ; Hill RS; Partlow JN; Yoo SY; Lam AT; Nasir R; Al-Saffar M; Barkovich AJ; Schwede M; Nagpal S; Rajab A; DeBerardinis RJ; Housman DE; Mochida GH; Morrow EM
    Proc Natl Acad Sci U S A; 2016 Sep; 113(38):E5598-607. PubMed ID: 27601654
    [TBL] [Abstract][Full Text] [Related]  

  • 10. EGFR gene copy number predicts response to anti-EGFR treatment in RAS wild type and RAS/BRAF/PIK3CA wild type metastatic colorectal cancer.
    Ålgars A; Sundström J; Lintunen M; Jokilehto T; Kytölä S; Kaare M; Vainionpää R; Orpana A; Österlund P; Ristimäki A; Carpen O; Ristamäki R
    Int J Cancer; 2017 Feb; 140(4):922-929. PubMed ID: 27879995
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Addiction to Coupling of the Warburg Effect with Glutamine Catabolism in Cancer Cells.
    Smith B; Schafer XL; Ambeskovic A; Spencer CM; Land H; Munger J
    Cell Rep; 2016 Oct; 17(3):821-836. PubMed ID: 27732857
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Retrospective study of RAS/PIK3CA/BRAF tumor mutations as predictors of response to first-line chemotherapy with bevacizumab in metastatic colorectal cancer patients.
    Nakayama I; Shinozaki E; Matsushima T; Wakatsuki T; Ogura M; Ichimura T; Ozaka M; Takahari D; Suenaga M; Chin K; Mizunuma N; Yamaguchi K
    BMC Cancer; 2017 Jan; 17(1):38. PubMed ID: 28068936
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutational profiling of colorectal cancers with microsatellite instability.
    Lin EI; Tseng LH; Gocke CD; Reil S; Le DT; Azad NS; Eshleman JR
    Oncotarget; 2015 Dec; 6(39):42334-44. PubMed ID: 26517354
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic role of tumor PIK3CA mutation in colorectal cancer: a systematic review and meta-analysis.
    Mei ZB; Duan CY; Li CB; Cui L; Ogino S
    Ann Oncol; 2016 Oct; 27(10):1836-48. PubMed ID: 27436848
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aspirin exerts high anti-cancer activity in
    Gu M; Nishihara R; Chen Y; Li W; Shi Y; Masugi Y; Hamada T; Kosumi K; Liu L; da Silva A; Nowak JA; Twombly T; Du C; Koh H; Li W; Meyerhardt JA; Wolpin BM; Giannakis M; Aguirre AJ; Bass AJ; Drew DA; Chan AT; Fuchs CS; Qian ZR; Ogino S
    Oncotarget; 2017 Oct; 8(50):87379-87389. PubMed ID: 29152088
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutant PIK3CA promotes cell growth and invasion of human cancer cells.
    Samuels Y; Diaz LA; Schmidt-Kittler O; Cummins JM; Delong L; Cheong I; Rago C; Huso DL; Lengauer C; Kinzler KW; Vogelstein B; Velculescu VE
    Cancer Cell; 2005 Jun; 7(6):561-73. PubMed ID: 15950905
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Coexistent mutations of KRAS and PIK3CA affect the efficacy of NVP-BEZ235, a dual PI3K/MTOR inhibitor, in regulating the PI3K/MTOR pathway in colorectal cancer.
    Kim A; Lee JE; Lee SS; Kim C; Lee SJ; Jang WS; Park S
    Int J Cancer; 2013 Aug; 133(4):984-96. PubMed ID: 23475782
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aspirin-Induced Chemoprevention and Response Kinetics Are Enhanced by PIK3CA Mutations in Colorectal Cancer Cells.
    Zumwalt TJ; Wodarz D; Komarova NL; Toden S; Turner J; Cardenas J; Burn J; Chan AT; Boland CR; Goel A
    Cancer Prev Res (Phila); 2017 Mar; 10(3):208-218. PubMed ID: 28154202
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of Concurrent PIK3CA Mutations on Response to EGFR Tyrosine Kinase Inhibition in EGFR-Mutant Lung Cancers and on Prognosis in Oncogene-Driven Lung Adenocarcinomas.
    Eng J; Woo KM; Sima CS; Plodkowski A; Hellmann MD; Chaft JE; Kris MG; Arcila ME; Ladanyi M; Drilon A
    J Thorac Oncol; 2015 Dec; 10(12):1713-9. PubMed ID: 26334752
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Landscape of Therapeutic Cooperativity in KRAS Mutant Cancers Reveals Principles for Controlling Tumor Evolution.
    Anderson GR; Winter PS; Lin KH; Nussbaum DP; Cakir M; Stein EM; Soderquist RS; Crawford L; Leeds JC; Newcomb R; Stepp P; Yip C; Wardell SE; Tingley JP; Ali M; Xu M; Ryan M; McCall SJ; McRee AJ; Counter CM; Der CJ; Wood KC
    Cell Rep; 2017 Jul; 20(4):999-1015. PubMed ID: 28746882
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.